Table 1.
Clinical characteristics of patients with BTC in the recurrence and nonrecurrence groups.
| Recurrence group | Nonrecurrence group | P value | |
|---|---|---|---|
| No. of patients | 13 | 9 | |
| Sex (men/women) | 10/3 | 7/2 | 1.000 |
| Age, years, mean ± SD | 67.0 ± 12.8 | 63.1 ± 9.4 | 0.448 |
| Disease type | 0.648 | ||
| Bile duct cancer | 8 (61.5%) | 7 (77.8%) | |
| Gallbladder cancer | 3 (23.0%) | 2 (22.2%) | |
| Ampulla of vater cancer | 2 (15.4%) | 0 (0%) | |
| Pathological TNM staging | |||
| (I/II/III/IV) | 4/9/0/0 | 5/3/1/0 | 0.384 |
| CA19-9 (U/mL) | 30.2 ± 32.4 | 28.6 ± 27.5 | 0.324 |
| ≤37 | 8 (61.5%) | 6 (66.6%) | |
| >37 | 5 (38.5%) | 3 (33.3%) | |
| CEA (ng/mL) | 30.2 ± 32.4 | 28.6 ± 27.5 | 0.117 |
| ≤5 | 8 (61.5%) | 6 (66.6%) | |
| >5 | 5 (38.5%) | 3 (33.3%) | |
| Pathological differentiation | 0.958 | ||
| Well-differentiated | 4 (30.8%) | 3 (33.3%) | |
| Moderately differentiated | 7 (53.8%) | 5 (55.6%) | |
| Poorly differentiated | 2 (15.4%) | 1 (11.1%) | |
| Lymph metastasis (yes/no) | 7/6 | 3/6 | 0.415 |
Abbreviations: BTC, bile tract cancer; SD, standard deviation; CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen.